12 February 2018 - Icon Bioscience today announced that the United States FDA has approved the company's new drug application for Dexycu (dexamethasone intra-ocular suspension), a dropless, long-acting therapeutic for treating inflammation associated with cataract surgery.

Icon Bioscience noted that in the US alone, over four million cataract surgeries are performed annually and that current standard of care for inflammation associated with the surgery involves a relatively arduous process by which patients, in a largely elderly population, assume the post-surgical responsibility of self-administering medicated eye drops, several times daily over a period of weeks.

Read Icon Bioscience press release